Open AccessSerum Overexpression of MicroRNA-10b in Patients with Bone Metastatic Primary Breast Cancer
Author(s) -
Fang Zhao,
Hu Gd,
Wang Xf,
Zhang Xh,
Zhang Yk,
Yu Zs
Publication year - 2012
Publication title -
journal of international medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 57
eISSN - 1473-2300
pISSN - 0300-0605
DOI - 10.1177/147323001204000304
Subject(s) - medicine , breast cancer , microrna , bone metastasis , metastasis , oncology , biomarker , breast carcinoma , cancer , receiver operating characteristic , real time polymerase chain reaction , pathology , biochemistry , chemistry , gene
OBJECTIVE: Bone metastasis is a major complication of advanced breast cancer. The present prospective case—control study investigated the involvement of microRNA (miR)-10b in the development of bone metastasis arising from primary breast carcinoma. METHODS: Serum miR-10b concentrations were determined by quantitative real-time reverse transcription—polymerase chain reaction in 122 patients with breast cancer, with or without bone metastases, and 59 age-matched healthy control subjects. RESULTS: Serum miR-10b concentrations were significantly higher in patients with bone metastases than in patients without bone metastases or control subjects. Serum miR-10b had an area under the receiver operating characteristic curve for the presence of bone metastases of 0.769, with 64.8% sensitivity and 69.5% specificity. CONCLUSION: These results suggest that serum miR-10b may be a useful biomarker for the identification of bone metastatic breast cancer.